Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Urologie 8/2014

01-12-2014

Het niet-spierinvasieve blaascarcinoom: een retrospectieve kwaliteitscontrolestudie

Auteurs: drs. N.F. Casteleijn, drs. D.M. Hakvoort, H. Peper, prof. dr. J. van der Palen, dr. E.B. Cornel

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 8/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Introductie

Er is weinig bekend over transurethrale resecties (TUR) voor niet-spierinvasieve blaascarcinomen (NMIBC) in niet-academische ziekenhuizen. Daarom is analyse van TUR bij NMIBC in een niet-academisch centrum van belang.

Methode

Patiënten met primair NMIBC, in de periode 2000-2010, zijn retrospectief geïncludeerd. Het diagnostisch en therapeutisch proces is geanalyseerd en vergeleken met de EORTC-risicotabellen.

Resultaten

In totaal werd bij 506 patiënten een primaire TUR-blaas uitgevoerd. Bij 95 (19%) patiënten bleek de primaire tumor reeds te zijn doorgegroeid tot in de detrusorspier. Bij vijf (1%) patiënten was er enkel sprake van carcinoom in situ (CIS) en bij twee patiënten was de stadiëring onduidelijk. 404 patiënten werden gediagnosticeerd met NMIBC: 71% pTa en 29% pT1. Het recidiefpercentage was niet afhankelijk van de operateur, post-TUR MMC, detrusorweefsel in het resectiepreparaat of de wachttijd. In ons cohort waren de recidiefpercentages na 1 jaar voor de EORTC-risicogroepen 0, 1-4 en 5-9 respectievelijk 14%, 19% en 16%, een significant lager recidiefpercentage voor de risicogroepen 1-4 en 5-9 in vergelijking met EORTC-recidiefpercentages.

Conclusie

Het recidiefpercentage in ons cohort was niet afhankelijk van de TUR-uitvoerende uroloog, post-TUR MMC, detrusorweefsel in het resectiepreparaat of de wachttijd. Ons recidiefpercentage na 1 jaar in de intermediaire EORTCrisicogroep was significant lager dan in de EORTC-risicotabellen.
Literatuur
1.
go back to reference Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997–1008.PubMedCrossRef Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997–1008.PubMedCrossRef
2.
go back to reference Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol. 2009;56(6):903–10.PubMedCrossRef Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol. 2009;56(6):903–10.PubMedCrossRef
3.
go back to reference Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–31.PubMedCrossRef Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–31.PubMedCrossRef
4.
go back to reference Pan D, Soloway MS. The importance of transurethral resection in managing patients with urothelial cancer in the bladder: proposal for a transurethral resection of bladder tumor checklist. Eur Urol. 2012;61(6):1199–1203.PubMedCrossRef Pan D, Soloway MS. The importance of transurethral resection in managing patients with urothelial cancer in the bladder: proposal for a transurethral resection of bladder tumor checklist. Eur Urol. 2012;61(6):1199–1203.PubMedCrossRef
5.
go back to reference Herr HW. Surgical factors in the treatment of superficial and invasive bladder cancer. Urol Clin North Am. 2005;32(2): 157–64.PubMedCrossRef Herr HW. Surgical factors in the treatment of superficial and invasive bladder cancer. Urol Clin North Am. 2005;32(2): 157–64.PubMedCrossRef
6.
go back to reference Roupret M, Yates DR, Varinot J, et al. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. Can J Urol. 2012;19(5):6459–64.PubMed Roupret M, Yates DR, Varinot J, et al. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. Can J Urol. 2012;19(5):6459–64.PubMed
7.
go back to reference Mariappan P, Finney SM, Head E, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new nonmuscle- invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 2012;109(11): 1666–73.PubMedCrossRef Mariappan P, Finney SM, Head E, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new nonmuscle- invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 2012;109(11): 1666–73.PubMedCrossRef
8.
go back to reference Kurth K, Denis L, Sylvester R, de Pauw M. The natural history and the prognosis of treated superficial bladder cancer. EORTC GU Group. Prog Clin Biol Res 1992;378:1–7.PubMed Kurth K, Denis L, Sylvester R, de Pauw M. The natural history and the prognosis of treated superficial bladder cancer. EORTC GU Group. Prog Clin Biol Res 1992;378:1–7.PubMed
9.
go back to reference Sylvester RJ, Meijden AP van der, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-5; discussion 475–7. Sylvester RJ, Meijden AP van der, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-5; discussion 475–7.
10.
go back to reference Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009;22(2):70–95.CrossRef Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009;22(2):70–95.CrossRef
11.
go back to reference Sylvester RJ, Oosterlinck W, Meijden AP van der. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6):2186–90.PubMedCrossRef Sylvester RJ, Oosterlinck W, Meijden AP van der. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6):2186–90.PubMedCrossRef
12.
go back to reference Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843–9.PubMedCrossRef Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843–9.PubMedCrossRef
13.
go back to reference Stenzl A, Cowan NC, Santis M de, et al. Treatment of muscleinvasive and metastatic bladder cancer: update of the EAU guidelines. Actas Urol Esp. 2012;36(8):449–60.PubMedCrossRef Stenzl A, Cowan NC, Santis M de, et al. Treatment of muscleinvasive and metastatic bladder cancer: update of the EAU guidelines. Actas Urol Esp. 2012;36(8):449–60.PubMedCrossRef
14.
go back to reference Kulkarni GS, Urbach DR, Austin PC, et al. Longer wait times increase overall mortality in patients with bladder cancer. J Urol. 2009;182(4):1318–24.PubMedCrossRef Kulkarni GS, Urbach DR, Austin PC, et al. Longer wait times increase overall mortality in patients with bladder cancer. J Urol. 2009;182(4):1318–24.PubMedCrossRef
15.
go back to reference Croft AM, Lynch P, Smellie JS, Dickinson CJ. Outpatient waiting times: indicators of hospital performance? J R Army Med Corps. 1998;144(3):131–7.PubMedCrossRef Croft AM, Lynch P, Smellie JS, Dickinson CJ. Outpatient waiting times: indicators of hospital performance? J R Army Med Corps. 1998;144(3):131–7.PubMedCrossRef
16.
go back to reference Meijden A van der, Sylvester R, Collette L, et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol. 2000;164(5):1533–7.CrossRef Meijden A van der, Sylvester R, Collette L, et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol. 2000;164(5):1533–7.CrossRef
Metagegevens
Titel
Het niet-spierinvasieve blaascarcinoom: een retrospectieve kwaliteitscontrolestudie
Auteurs
drs. N.F. Casteleijn
drs. D.M. Hakvoort
H. Peper
prof. dr. J. van der Palen
dr. E.B. Cornel
Publicatiedatum
01-12-2014
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Urologie / Uitgave 8/2014
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI
https://doi.org/10.1007/s13629-014-0110-8

Andere artikelen Uitgave 8/2014

Tijdschrift voor Urologie 8/2014 Naar de uitgave

EditorialNotes

Editorial